patients were stratified according to er status and dominant site of disease and randomized to one of three regimens : cyclophosphamide , 5-fluorouracil , and prednisone ( cfp ) versus cfp , methotrexate , and vincristine ( cfpmv ) versus doxorubicin and cyclophosphamide ( ac ) .
C0016360
5-fluorouracil
C0055162
cfp